EE03783B1 - A pharmaceutical composition for the treatment of epitheliomas and the use of an antibody or antibody molecule - Google Patents

A pharmaceutical composition for the treatment of epitheliomas and the use of an antibody or antibody molecule

Info

Publication number
EE03783B1
EE03783B1 EE9800164A EE9800164A EE03783B1 EE 03783 B1 EE03783 B1 EE 03783B1 EE 9800164 A EE9800164 A EE 9800164A EE 9800164 A EE9800164 A EE 9800164A EE 03783 B1 EE03783 B1 EE 03783B1
Authority
EE
Estonia
Prior art keywords
antibody
epitheliomas
treatment
pharmaceutical composition
antibody molecule
Prior art date
Application number
EE9800164A
Other languages
Estonian (et)
Other versions
EE9800164A (en
Inventor
Heider Karl-Heinz
Adolf G�nther
Ostermann Elinborg
Patzelt Erik
Sproll Marlies
Original Assignee
Boehringer Ingelheim International Gmbh
Forschungszentrum Karlsruhe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/en
Application filed by Boehringer Ingelheim International Gmbh, Forschungszentrum Karlsruhe Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of EE9800164A publication Critical patent/EE9800164A/en
Publication of EE03783B1 publication Critical patent/EE03783B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EE9800164A 1995-12-06 1996-12-05 A pharmaceutical composition for the treatment of epitheliomas and the use of an antibody or antibody molecule EE03783B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (en) 1995-12-06 1995-12-06 Diagnosis of squamous epithelial cell carcinoma
DE19615074 1996-04-17
PCT/EP1996/005448 WO1997021104A1 (en) 1995-12-06 1996-12-05 Method of diagnosing and treating epithelioma

Publications (2)

Publication Number Publication Date
EE9800164A EE9800164A (en) 1998-12-15
EE03783B1 true EE03783B1 (en) 2002-06-17

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800164A EE03783B1 (en) 1995-12-06 1996-12-05 A pharmaceutical composition for the treatment of epitheliomas and the use of an antibody or antibody molecule

Country Status (26)

Country Link
EP (1) EP0865609B1 (en)
JP (1) JP2000502067A (en)
KR (1) KR100473824B1 (en)
CN (1) CN1151377C (en)
AR (1) AR004360A1 (en)
AT (1) ATE235056T1 (en)
AU (1) AU726704B2 (en)
BG (1) BG62985B1 (en)
BR (1) BR9611901A (en)
CA (1) CA2239709A1 (en)
CO (1) CO4520233A1 (en)
CZ (1) CZ174198A3 (en)
DE (1) DE59610248D1 (en)
DK (1) DK0865609T3 (en)
EE (1) EE03783B1 (en)
ES (1) ES2190484T3 (en)
HK (1) HK1011560A1 (en)
MX (1) MX9804459A (en)
NO (1) NO319903B1 (en)
NZ (1) NZ324314A (en)
PL (1) PL184521B1 (en)
PT (1) PT865609E (en)
SK (1) SK284378B6 (en)
TR (1) TR199801027T2 (en)
UY (1) UY24389A1 (en)
WO (1) WO1997021104A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
YU91403A (en) * 2001-05-18 2006-05-25 Boehringer Ingelheim International Gmbh. Antibodies specific for cd44v6
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
RU2599447C2 (en) * 2010-02-04 2016-10-10 Юниверсити Оф Майами Monoclonal antibodies to cd44, intended for use in treating squamous cell carcinoma of the head and the neck
US9218450B2 (en) 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
AU2018409898A1 (en) * 2018-02-22 2020-09-24 Multitude Inc. Therapeutic antibody and uses thereof
WO2023227644A2 (en) 2022-05-25 2023-11-30 Akiram Therapeutics Ab Binding protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0703989T3 (en) * 1993-06-18 1998-02-09 Biotie Therapies Oy Preparations and Diagnostic Methods Using Monoclonal Antibodies to CD44v6
WO1995000851A1 (en) * 1993-06-22 1995-01-05 Boehringer Ingelheim International Gmbh Method for the diagnosis and analysis of tumours
DE4326573A1 (en) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Polypeptides encoded by exon v5 of the CD44 gene as targets for immunotherapy and immunoscintigraphy of tumors
UA58482C2 (en) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх MONOCLONAL ANTIBODY VFF-18 AGAINST CD44v6 AND ITS FRAGMENTS

Also Published As

Publication number Publication date
CO4520233A1 (en) 1997-10-15
MX9804459A (en) 1998-09-30
WO1997021104A1 (en) 1997-06-12
NO319903B1 (en) 2005-09-26
BG102513A (en) 1999-02-26
AR004360A1 (en) 1998-11-04
AU1177397A (en) 1997-06-27
PL327066A1 (en) 1998-11-23
KR100473824B1 (en) 2005-09-30
ES2190484T3 (en) 2003-08-01
AU726704B2 (en) 2000-11-16
ATE235056T1 (en) 2003-04-15
EP0865609A1 (en) 1998-09-23
CN1151377C (en) 2004-05-26
EE9800164A (en) 1998-12-15
DK0865609T3 (en) 2003-06-23
PT865609E (en) 2003-08-29
CN1207811A (en) 1999-02-10
DE59610248D1 (en) 2003-04-24
NO982588D0 (en) 1998-06-05
EP0865609B1 (en) 2003-03-19
JP2000502067A (en) 2000-02-22
KR19990071952A (en) 1999-09-27
SK284378B6 (en) 2005-02-04
SK73698A3 (en) 1999-01-11
HK1011560A1 (en) 1999-07-16
NO982588L (en) 1998-08-05
UY24389A1 (en) 2001-10-25
BG62985B1 (en) 2000-12-29
BR9611901A (en) 1999-03-02
NZ324314A (en) 2000-02-28
TR199801027T2 (en) 1998-10-21
CZ174198A3 (en) 1999-02-17
PL184521B1 (en) 2002-11-29
CA2239709A1 (en) 1997-06-12

Similar Documents

Publication Publication Date Title
BR9611986A (en) Process compounds for the preparation of the same pharmaceutical composition and use of the compounds
FI953479A0 (en) 1-Arylpyrimidine derivatives and their pharmaceutical use
NO20004345L (en) Pharmaceutical composition
BR1100824A (en) Pharmaceutical composition and composition
BR9500784A (en) Compound and pharmaceutical formulation
BR9504060A (en) Compound and pharmaceutical formulation
NO954146D0 (en) Coated pharmaceutical preparations
BR9607317A (en) Peptides and pharmaceutical composition
BR9607318A (en) Peptides and pharmaceutical composition
BR9602705A (en) Compound pharmaceutical composition process for the preparation of a compound and use
FI944832A (en) Pharmaceutical composition
EE03783B1 (en) A pharmaceutical composition for the treatment of epitheliomas and the use of an antibody or antibody molecule
EE200000226A (en) 3,6-Half-Ketals of the 9a-Azalides, Method of Preparation and Pharmaceutical Composition
ITMI932540A0 (en) PHARMACEUTICAL COMPOSITION
BR9509688A (en) Pharmaceutical composition and composition
LV11727A (en) Pharmaceutical composition
FI973229A (en) New pharmaceutical composition
FI973280A0 (en) Pharmaceutical composition
FI964113A (en) A pharmaceutical composition for the treatment of tardive dyskinesia and its use
BR9610851A (en) Compound compound preparation process medicine pharmaceutical composition and use of the compound
LV10579A (en) Pharmaceutical composition
BR9606066A (en) Compound and pharmaceutical formulation
BR9605777A (en) Pharmaceutical composition
BR9605131A (en) Pharmaceutical composition
BR9505130A (en) Pharmaceutical composition and composition

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

MM4A Lapsed by not paying the annual fees

Effective date: 20051205